A
Andrew J. Martin
Researcher at University of New South Wales
Publications - 897
Citations - 43053
Andrew J. Martin is an academic researcher from University of New South Wales. The author has contributed to research in topics: Medicine & Academic achievement. The author has an hindex of 84, co-authored 819 publications receiving 36203 citations. Previous affiliations of Andrew J. Martin include University of Western Australia & Max Planck Society.
Papers
More filters
Journal ArticleDOI
What happens when students reflect on their self-efficacy during a test? Exploring test experience and test outcome in science
Andrew J. Martin,Lars-Erik Malmberg,Roger Kennett,Marianne Mansour,Brad Papworth,Joel Pearson +5 more
TL;DR: In this article, the authors investigated real-time perceived science competence (via self-efficacy) as one such factor and found that prior performance was significantly and positively associated with subsequent performance.
Journal ArticleDOI
Structure-Function Relationships of Anti-DNA Antibodies
TL;DR: Clinically, anti-dsDNA antibodies often reflect disease activity and are associated with the presence of active lupus nephritis, and there is evidence to support the deposition of circulating immune complexes containing DNA and anti-DNA antibodies.
Journal ArticleDOI
Compensated pathogenic deviations.
Anja Barešić,Andrew J. Martin +1 more
TL;DR: Although it is clear that these effects occur in proteins, compensatory mutations are also important in RNA potentially having an impact on disease, and RNA provides an interesting model for understanding mechanisms of compensatory effects, both by looking at naturally occurring RNA molecules and as a means of computational simulation.
Journal ArticleDOI
EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).
Ian D. Davis,Anne Long,Andrew J. Martin,David Espinoza,Sonia Yip,Ganessan Kichenadasse,Jennifer F. Thompson,Michelle Harrison,Ray M. Lowenthal,Nick Pavlakis,Arun Azad,George Kannourakis,Christopher Steer,David Goldstein,Jeremy Shapiro,Martin R. Stockler +15 more
TL;DR: A single-arm, two-stage, multicenter, phase II trial to determine the activity, feasibility, and safety of sunitinib 50mg daily 4 weeks on / 2wk off, alternating with everolimus 10mg daily for 5 wk on / 1 wk off for VEGFR and mTOR pathways.
Journal ArticleDOI
What does the EPOCH (early prevention of obesity in childhood) prospective meta-analysis tell us about early life obesity prevention?
Lisa M. Askie,Andrew J. Martin,David Espinoza,Karen J. Campbell,Lynne Daniels,Kylie D. Hesketh,Anthea Margarey,Chris Rissel,Barry J Taylor,Rachael W. Taylor,Li Meing Wen,Louise A. Baur +11 more
TL;DR: It is suggested that body fat % via eyeballing and comparing the THEN to the NOW is probably the most practically effective method of identifying these clients.